Patents Examined by John Kight
  • Patent number: 6197966
    Abstract: A method for producing an optically active amino alcohol compound of the formula [3], an enantiomer thereof or a salt thereof, comprising reacting a mesoepoxide compound of the formula [1] with a compound of the formula [2] in the presence of a mixed catalyst comprising a Lewis acid and a proton donor: wherein R1, R2 and R3 are each H, an optionally substituted lower alky, and the like, or R1 and R1 or R2 and R3 may form an optionally substituted ring; and R4 and R5 are each H, an optionally substituted lower alkyl, and the like, or R4 and R5 may form an optionally substituted ring together with the adjacent N, or an imide group or azide group together with the adjacent N, and R6 is H or a silyl group. The present invention enables stereoselective production of a desired intermediate compound, which is an HIV protease inhibitor, extremely efficiently as compared to conventional methods.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: March 6, 2001
    Assignees: Japan Tobacco Inc., Agouron Pharmaceuticals, Inc.
    Inventors: Takashi Inaba, Shoichi Sagawa, Hiroyuki Abe
  • Patent number: 6194405
    Abstract: This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is zero to 6; p and q are zero to 4; r is zero to 5; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; halomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, halomethyl, halomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or halomethyl; X is CR6R7, NR8, O, S, S(═O) or S(═O)2; aryl is optionally substituted phenyl; provided that the compound is other than (±)-3,3a,8,12b-tetrahydro-N-methyl-2H-dibenzo[3
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: February 27, 2001
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Pilar Gil-Lopetegui, Francisco Javier Fernández-Gadea, Theo Frans Meert
  • Patent number: 6191164
    Abstract: Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them Chromans of the formula I and of the formula 1a having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+ channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: February 20, 2001
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Hans Jochen Lang, Uwe Gerlach, Joachim Brendel, Henrich Christian Englert, Heinz Gögelein, Max Hropot, Helmut Bohn, Andreas Herling, Andreas Busch, Rainer Greger
  • Patent number: 6191147
    Abstract: The present invention is directed to compounds of the formula: and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same, where R1, R2, R3, R4, R5, R6, R7 and X are defined herein.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: February 20, 2001
    Assignees: PPD Discovery, Inc., Duke University
    Inventors: Bradley B. Brown, Patrick J. Casey, Casey Pritchard Purdy, Zita Latona, Sarah Tavares
  • Patent number: 6191118
    Abstract: An erythromycin A derivative represented by Formula wherein R1 is a group represented by the formula: a group represented by the formula: (c) pyridylacetyl, (d) cycloalkylmethyl or (e) 1,2 bis-(ethoxycarbonyl)vinyl, R2 is the same group as defined for R1, hydrogen, alkyl, alkanoyl, alkoxycarbonyl, R1 and R2 together may form ═CH—R14, or R1 and R2 together with the nitrogen atom to which they are attached may form: R3 is hydrogen, alkyl or cinnamyl, R4 is hydrogen, acetyl, ethylsuccinyl or nicotinoyl, A is —OC(═O)—R17, —OC(═O)—CH2—R17, —OC(═O)—NH—R17, —O—R17 or —OC(═O)—O—R17, and R5 and R6 are each hydrogen or alkyl.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: February 20, 2001
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Toshifumi Asaka, Masato Kashimura, Akiko Matsuura, Tomohiro Sugimoto, Tetsuya Tanikawa, Takaaki Ishii
  • Patent number: 6187782
    Abstract: Novel morphinan derivatives and pharmaceutically acceptable acid addition salts thereof as compounds having abilities to bind to opioid &egr;-receptor, which have agonist or antagonist activities, are disclosed. The morphinan derivatives according to the present invention are represented by the formula (I).
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: February 13, 2001
    Assignee: Toray Industries, Inc.
    Inventors: Hiroshi Nagase, Hideaki Fujii, Takashi Endoh, Koji Kawai
  • Patent number: 6187933
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: February 13, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Vidyasagar Vuligonda, Min Teng, Richard L. Beard, Alan T. Johnson, Yuan Lin, Roshantha A. Chandraratna
  • Patent number: 6184380
    Abstract: A process for preparing a naphthyridone carboxylic acid and its derivatives makes use of side chain intermediates of formulae I and IV herein.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: February 6, 2001
    Assignee: Pfizer Inc.
    Inventors: Charles K. Chiu, Lewin T. Wint
  • Patent number: 6184238
    Abstract: An N-hydroxyurea derivative having an antiallergic action or anti-inflammatory action having the formula wherein, either one of R1, R3, and R4 represents A, either one of the other groups of R1, R3, and R4 and R2 represents a 3-pyridyl group or 3-pyridylalkyl group, the remaining groups of R1, R2, R3, and R4 independently represent a hydrogen atom, halogen atom, or a substituted or unsubstituted C1 to C8 alkyl group, R5 represents a hydrogen atom or lower alkyl group, R6 represents a hydrogen atom, lower alkyl group, C3 to C7 cycloalkyl group, or a substituted or unsubstituted phenyl group, where the substituent represents a halogen atom, lower alkyl group, or lower alkoxy group, B represents a bond, C1 to C20 alkylene group, C2 to C8 alkenylene group, or C2 to C8 alkynylene group or B—C(R5) represents a C2 to C6 alkylene group having a benzene ring in the middle thereof or its pharmacologically acceptable salt or the hydrate or solvate thereof.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: February 6, 2001
    Assignee: Nikken Chemicals Co., Ltd.
    Inventors: Michika Takano, Toshiya Komatsu, Yoshikazu Kawahara
  • Patent number: 6184228
    Abstract: The present invention is directed to a method for selecting compounds for use in treating sickle cell disease in a patient. The method comprises the steps of selecting a first set of HbS ligands from a first group of chemical compounds, selecting from the first set of HbS ligands a seconds set that exhibit inhibition of HbS polymerization, and selecting from the second set a third set that display anti-sickling activity of red blood cells when in the presence thereof. The method may include the step of performing a methemoglobin S proteolysis assay measuring a percent protease protection for each compound. The method may additionally include the steps of measuring HbS aggregation, inhibition of protease, deoxy-HbS gelation inhibition activity, O2 affinity of HbS, and cytotoxic effect to cell activity. The method may further include assessing red blood cell morphology, and eliminating compounds that contain moieties that bind to heme.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: February 6, 2001
    Assignee: ANADYS Pharmaceuticals, Inc.
    Inventors: Alan F. Corin, Andrew A. Pakula, Julianne Bryan
  • Patent number: 6184221
    Abstract: Compounds of the formula I having the meanings of the substituents indicated in the claims are outstandingly active substances for the production of medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal illnesses.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: February 6, 2001
    Assignee: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Uwe Gerlach, Hans Jochen Lang, Klaus Weidmann, Joachim Brendel
  • Patent number: 6180642
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: January 30, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Thomas F. Walsh, Feroze Ujjainwalla
  • Patent number: 6180804
    Abstract: A working solution for producing hydrogen peroxide, containing an alkylanthraguinone working compound dissolved in a solvent, is regenerated by contacting the working solution with a catalyst containing from 5% to 100% boehmite at a temperature of 25° C. to 150° C. At least a portion of the tetrahydro-alkylanthraquinone epoxide present in the working solution is converted to working compound to maintain the composition of the working solution within specified limits.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: January 30, 2001
    Assignee: FMC Corporation
    Inventor: Edward F. Dougherty
  • Patent number: 6180801
    Abstract: The present invention intends to provide a method for producing 3-isochromanones represented by formula (II) useful as a synthetic starting material of medicals or agricultural chemicals and the cyano compound represented by formula (I) by an industrially advantageous method in a high yield. Disclosed herein is a method for manufacturing a 3-isochromanone represented by the following formula (II): (wherein R2, R3, R4 and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group or an alkoxy group), said method is characterized by comprising the steps of: hydrolyzing a cyano compound represented by formula (I): (wherein R1 represents a hydrogen atom, an alkyl group or an aryl group, and R2, R3, R4 and R5 have the same meanings as defined above) and subjecting the hydrolyzate to intra-molecular cyclization.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: January 30, 2001
    Assignee: Showa Denko Kabushiki Kaisha
    Inventors: Hiroyuki Monzen, Hideo Miyata, Kimitaka Ooshiro, Kohei Morikawa
  • Patent number: 6180652
    Abstract: The present invention provides acetone complexes of sulfoxide compounds, useful as medicines such as inhibitors of gastric acid secretion and anti-ulcer agents or as intermediates for production of medicines, a process for producing the same and a purification method of using the same. Namely, it is the acetone complexes of sulfoxide compounds or of pharmaceutically acceptable salts thereof represented by the following formula: (wherein R1 represents a hydrogen atom, a methoxy group or a difluoromethoxy group, R2 represents a methyl group or a methoxy group, R3 represents a 3-methoxypropoxy group, a methoxy group or a 2,2,2-trifluoroethoxy group, R4 represents a hydrogen atom or a methyl group, n and m independently represent an integer of 1 to 4, and B represents a hydrogen atom, an alkali metal atom or ½ alkaline earth metal atom), which are obtained by treating the sulfoxide compounds or pharmaceutically acceptable salts thereof with acetone.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: January 30, 2001
    Assignee: Eisai Co., Ltd.
    Inventors: Masahiko Tsujii, Nobuo Niikawa, Keizo Takayanagi, Shigeharu Nochi
  • Patent number: 6177457
    Abstract: A process for preparing compounds of the formula: and intermediates for use in the process.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: January 23, 2001
    Assignee: Glaxo Wellcome S.A.
    Inventors: Jose Maria Bueno Calderon, Jesus Chicharro Gonzalo, Jose Fiandor Roman, Sophie Huss, Brian Arthur Michael Rudd
  • Patent number: 6177567
    Abstract: A method for the preparation of oxycodone, and salts thereof, from codeine comprising oxidation of codeine to codeinone, formation of an dienolsilyl ether congener of codeinone in strong amine base, oxidation of the dienolsilyl ether congener using peracetic acid, and hydrogenation of the resulting 14-hydroxycodeinone product.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: January 23, 2001
    Assignee: Boehringer Ingelheim Chemicals, Inc.
    Inventors: Fang-Ting Chiu, Young S. Lo
  • Patent number: 6177419
    Abstract: Compounds and methods of preparing compounds represented by structural formula (I): wherein X represents any suitable counter-anion; R1 and R2 independently represent hydrogen, C1-6 alkoxy or nitro; R3, R4, R5 and R6 each independently represents hydrogen, hydroxy, halo, C1-6 alkyl, C2-6 alkenyl or C1-6 alkoxy; and R7, R8, R9 and R10 each independently represents hydrogen, hydroxy, halo, C1-6 alkyl, C2-6 alkenyl or C1-6 alkoxy. Compounds represented by structural formula (I) are useful in treating or preventing free radical-associated diseases or conditions in mammals.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: January 23, 2001
    Assignee: Eukarion, Inc.
    Inventors: Ian Baxter Campbell, Ann Louise Walker, Philip Charles Box, Gerard Martin Paul Giblin, George Edward Tranter
  • Patent number: 6177449
    Abstract: Compounds of the formula I having the meanings of the substituents indicated in the claims are outstandingly efficacious substances for producing medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal disorders.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: January 23, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Joachim Brendel, Uwe Gerlach, Hans Jochen Lang, Klaus Weidmann
  • Patent number: 6174903
    Abstract: The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein Z, R, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to said mammal.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: January 16, 2001
    Assignee: Pfizer Inc.
    Inventors: Joseph P. Lyssikatos, Bingwei V. Yang